SCHEMBL21947554

SCHEMBL21947554

COc1ccc(S(=O)(=O)NC2CCOC2)cc1C(=O)Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 1/20 0.51
HTR2B P41595 1/20 0.50
MAPT P10636 5/20 0.49
TP53 P04637 4/20 0.49
LMNA P02545 3/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
NPC1 O15118 3/20 0.45
THRB P10828 1/20 0.45
POLB P06746 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569267 1.00 GSTO1 (0.51) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21545349 0.92 HTR2B (0.54) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21545661 0.92 HTR2B (0.56) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21545347 0.92 HTR2B (0.54) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21545662 0.92 HTR2B (0.56) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21569361 0.91 TP53 (0.56) HTR2BMAPTTP53LMNAMEN1
SCHEMBL21947439 0.91 TP53 (0.56) HTR2BMAPTTP53LMNAMEN1
SCHEMBL21545652 0.90 HTR2B (0.46) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21947500 0.89 MAPT (0.56) GSTO1HTR2BMAPTTP53LMNA
SCHEMBL21545552 0.89 MAPT (0.53) HTR2BMAPTTP53LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654837-B2 Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654837-B2 Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis HTR2B, HTR3B, HTR1A GSTO1 1258/4885HTR2B 1/4885MAPT 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.